Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results

Contributed by: Business Wire

Logo

Tags

Health

Genetics

Other Health

Clinical Trials

Pharmaceutical

Biotechnology

Silence Therapeutics plc

More Like This

Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results

Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update